Metronomic Chemotherapy Not Beneficial in Non-metastatic Osteosarcoma

Share this content:
Metronomic chemotherapy does not improve the event-free survival of patients with non-metastatic osteosarcoma.
Metronomic chemotherapy does not improve the event-free survival of patients with non-metastatic osteosarcoma.

Metronomic chemotherapy (MC) does not improve the event-free survival (EFS) of patients with non-metastatic osteosarcoma, according to a study published in Cancer.1

The standard chemotherapy for patients with high-grade, operable osteosarcoma is a combination of methotrexate, adriamycin, and cisplatin (MAP). For the present study, researchers hypothesized that adding a MC regimen, which is given at a low dose without large treatment-breaks, would improve EFS in this patient population.

This prospective, randomized study (ClinicalTrials.gov Identifier: NCT02273583) compared EFS in 2 treatment groups: MAP + MC, MAP alone. The MC component included cyclophosphamide and methotrexate.

Of 422 total registered participants, 139 were randomized to MAP + MC, while 157 were randomized to MAP alone. All randomized patients were included in the analysis, though 49 patients in the MAP + MC group did not initiate MC for varying reasons.

The mean EFS time was 51.58 months in the MAP-MC group and 58.81 months in the MAP group. The mean overall survival times were 65.82 months and 66.16 months for MAP + MC and MAP, respectively.

RELATED: Tivozanib Shows Antitumor Activity in Metastatic Soft Tissue Sarcoma

Three patients died from treatment-related toxicity in the MAP-MC group; 4 died from toxicity in the MAP group.

The authors conclude that this MC regimen should not be used in non-metastatic osteosarcoma. The treatment may, however, be useful in metastatic disease settings.

Reference

  1. Senerchia AA, Macedo CR, Ferman S, et al. Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment. Cancer. 2016 Nov 7. doi: 10.1002/cncr.30411 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters